Put companies on watchlist
AbbVie
ISIN: US00287Y1091
WKN: A1J84E
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

AbbVie · ISIN: US00287Y1091 · PR Newswire (ID: 20240827CG89825)
27 August 2024 02:05PM

SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator


  • SkinMedica®, by the makers of BOTOX® Cosmetic (onabotulinumtoxinA) launches the first and only product to use a proprietary complex of five forms of Hyaluronic Acid (HA) and Hydra Collagen, plus Advanced VITISENSCE® Technology for deeper hydration

IRVINE, Calif., Aug. 27, 2024 /PRNewswire/ -- For 25 years, SkinMedica® has been at the forefront of science-based skincare solutions, and today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of its next generation hydration product: SkinMedica® HA Hydra Collagen Replenish + Restore Hydrator. The product is specifically designed to deliver unparalleled hydration, visible plumpness, and radiance to facial skin. 

"We revolutionized the way people approached skin hydration in 2016 with the launch of our first HA Rejuvenating Hydrator, which continues to win industry awards and be a consumer favorite," said Jasson Gilmore, Senior Vice President of U.S. Aesthetics at Allergan Aesthetics. "Now we've taken the best of the original product and improved on it to enhance skin health and provide even deeper hydration."

The new SkinMedica® HA Hydra Collagen Replenish + Restore Hydrator has double the amount of hyaluronic acid than the original and now contains Hydra Collagen and Advanced VITISENSCE® Technology, which support the skin's natural ability to attract and retain moisture while providing instant hydration and smoothness. The product is appropriate for all skin types, helps fortify the skin barrier, and provides hydration for up to 48 hours1.

For optimal results, HA Hydra Collagen Replenish + Restore Hydrator can be complemented with an in-office DiamondGlow® facial using SkinMedica® HA Hydra Collagen Pro-Infusion Serum. Clinical studies show that participants using both the at-home and in-office treatment reported their skin appeared three-times more radiant, more hydrated, and visibly plumper after just one use1.

"Regardless of age, gender, or ethnicity, people experience dehydrated skin at some point. Skin hydration is critical for skin that not only looks smooth and radiant, but also feels healthy and firm," said Dr. Shannon Humphrey, board-certified dermatologist. "Daily application of the HA Hydra Collagen Hydrator, supplemented with DiamondGlow® treatments every 4-6 weeks is an effective combination that delivers radiant, glowing, and hydrated skin."

SkinMedica® HA Hydra Collagen Replenish + Restore Hydrator MSRP $192 is available for purchase at SkinMedica.com. To experience the SkinMedica® HA Hydra Collagen Pro-Infusion Serum for DiamondGlow®, find a provider by visiting DiamondGlow.com. For more information follow @SkinMedica on Instagram.

To learn more and earn points on your favorite aesthetic treatments, including SkinMedica®, join Allē, the number one aesthetics loyalty program at Alle.com.

About Allergan Aesthetics

At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skincare, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

BOTOX® COSMETIC IMPORTANT SAFETY INFORMATION AND APPROVED USES 

Approved Uses

BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, and frown lines between the eyebrows in adults. 

IMPORTANT SAFETY INFORMATION

BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic: 

  • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months. 
  • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing. 

BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.

There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, and/or forehead lines. 

BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of taking BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities. 

Serious and/or immediate allergic reactions have been reported. They include: itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint. 

Do not receive BOTOX® Cosmetic if you: are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® (rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or Xeomin® (incobotulinumtoxinA); have a skin infection at the planned injection site. 

Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including difficulty swallowing and difficulty breathing from typical doses of BOTOX® Cosmetic. 

Tell your doctor about all your medical conditions, including: plans to have surgery; had surgery on your face; have trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby); are breast-feeding or plan to (it is not known if BOTOX® Cosmetic passes into breast milk). 

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX® Cosmetic in the past. 

Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc®, Dysport®, or Xeomin® in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; take aspirin-like products or blood thinners. 

Other side effects of BOTOX® Cosmetic include: dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of your eyelids and dry eyes. 

For more information refer to the Medication Guide or talk with your doctor. 

To report a side effect, please call Allergan at 1-800-678-1605. 

Please see BOTOX® Cosmetic full Product Information including Boxed Warning and Medication Guide. 

DiamondGlow® Important Information

Uses

The DiamondGlow® device is a general dermabrasion device that gently removes the top layer of skin and delivers topical cosmetic serums onto the skin.

Important Safety Information

The DiamondGlow® treatment is not for everyone. You should not have a DiamondGlow® treatment if you have compromised skin quality. Tell your provider if you are pregnant or lactating, or if you have any medical conditions, including allergies, and if you are using topical medications on the area to be treated.

Typical side effects include a scratchy, stinging sensation during the treatment and temporary tightness, redness or slight swelling after the treatment. Rare serious side effects may also occur and include severe skin irritation and allergic reactions.

SkinMedica® Pro-Infusion Serums Disclaimer

SkinMedica® Pro-Infusion Serums are intended to meet the FDA's definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These products are not intended to be drugs that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA.

Please talk to your provider for additional information.

SkinMedica® Important Information

Most SkinMedica® products are intended to meet the FDA's definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These SkinMedica® products are not intended to be drug products that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA. 

For more information, please talk to your provider or visit SkinMedica.com and DiamondGlow.com. To report an adverse reaction, please call Allergan at 1-800-433-8871.

References:  

  1. Data on file at SkinMedica ® 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/skinmedica-revolutionizes-skin-hydration-with-the-introduction-of-ha5-hydra-collagen-replenish--restore-hydrator-302230995.html

SOURCE AbbVie

Visual performance / price development - AbbVie
Smart analysis and research tools can be found here.
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2024
PR Newswire
Contact:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942